Diagnostics and research stocks
The 74 diagnostics and research stocks we cover, part of healthcare, largest first. Numbers as of .
- Companies
- 74
- Combined market cap
- $972.5B
- Median PE
- 41.2×
- Median revenue growth
- +5.2%
- Median net margin
- −5.4%
| Company | Market cap | PE | P/S | Revenue growth | Net margin | Dividend yield |
|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientificcaveat | $256.9B | 36.7× | 5.4× | +8% | 14.9% | 0.26% |
| DHRDanahercaveat | $162.6B | 37.9× | 6.3× | +6% | 16.9% | 0.66% |
| NTRANatera | $56.2B | n/m | 20.7× | +38% | −7.1% | n/m |
| IDXXIDEXX Laboratories | $52.1B | 46.5× | 11.4× | +13% | 25.0% | n/m |
| AAgilent Technologies | $49.6B | 34.5× | 6.7× | +9% | 19.5% | 0.58% |
| WATWaters | $46.4B | 118× | 10.0× | +52% | 3.6% | n/m |
| IQVIQVIA | $42.5B | 32.0× | 2.5× | +8% | 8.1% | n/m |
| ILMNIllumina | $35.7B | 44.0× | 8.0× | +5% | 18.4% | n/m |
| MTDMettler-Toledo International | $34.2B | 38.4× | 8.3× | +7% | 21.9% | n/m |
| LHLabcorp | $28.9B | 29.4× | 2.0× | +6% | 7.0% | 0.81% |
| DGXQuest Diagnostics | $27.5B | 24.9× | 2.3× | +9% | 9.5% | 1.35% |
| GHGuardant Health | $23.7B | n/m | 20.0× | +43% | −38.3% | n/m |
| MEDPMedpace | $18.1B | 38.0× | 6.5× | +25% | 17.7% | n/m |
| RVTYRevvity | $16.9B | 72.2× | 5.8× | +4% | 8.2% | n/m |
| CRLCharles River Laboratories International | $16.2B | n/m | 4.0× | −1% | −6.0% | n/m |
| AVTRAvantor | $10.6B | n/m | 1.6× | −2% | −8.8% | n/m |
| BIOBio-Rad Laboratories | $9.8B | 44.4× | 3.8× | +1% | 8.6% | n/m |
| CAICaris Life Sciences | $9.1B | 86.8× | 9.2× | +85% | 10.6% | n/m |
| BRKRBruker | $8.5B | n/m | 2.4× | +2% | −2.0% | n/m |
| TXG10x Genomics | $8B | n/m | 13.0× | −4% | −12.2% | n/m |
| LNTHLantheus | $6.5B | 24.3× | 4.2× | +2% | 17.7% | n/m |
| GRALGRAIL | $6B | n/m | 36.2× | +23% | n/m | n/m |
| RDNTRadNet | $5.8B | n/m | 2.5× | +19% | −0.9% | n/m |
| BLLNBillionToOnecaveat | $5.2B | 170× | 13.1× | +90% | 9.5% | n/m |
| CDNACareDxcaveat | $4.5B | 35.9× | 9.1× | +39% | 25.9% | n/m |
| VCYTVeracyte | $3.9B | 35.0× | 7.0× | +17% | 20.4% | n/m |
| CELCCelcuity | $3.3B | n/m | n/m | n/m | n/m | n/m |
| NEOGNeogen | $2.6B | n/m | 2.9× | −0% | −6.3% | n/m |
| CLDXCelldex Therapeutics | $2.3B | n/m | n/m | −97% | n/m | n/m |
| ALMRAlamar Biosciencescaveat | $2B | n/m | n/m | n/m | n/m | n/m |
| FTREFortreacaveat | $1.9B | n/m | 0.7× | −3% | −2.6% | n/m |
| PSNLPersonalis | $1.7B | n/m | 24.2× | −13% | n/m | n/m |
| ABSIAbsci | $1.7B | n/m | n/m | −62% | n/m | n/m |
| NTLAIntellia Therapeutics | $1.6B | n/m | 27.5× | +13% | n/m | n/m |
| LMRILumexa Imagingcaveat | $1.1B | n/m | n/m | n/m | n/m | n/m |
| CSTLCastle Biosciences | $1.1B | n/m | 3.0× | +3% | −5.4% | n/m |
| QDELQuidelOrtho | $962.1M | n/m | 0.4× | −2% | −39.2% | n/m |
| CTKBCytek Biosciences | $750M | n/m | 3.6× | +5% | −39.0% | n/m |
| OABIOmniAb | $742.4M | n/m | 18.5× | +91% | n/m | n/m |
| PACBPacific Biosciences of California | $728.9M | n/m | 4.6× | +2% | −82.5% | n/m |
| ACHVAchieve Life Sciences | $680.2M | n/m | n/m | n/m | n/m | n/m |
| MYGNMyriad Genetics | $559.6M | n/m | 0.7× | −3% | −14.0% | n/m |
| NRCNRC Health | $536.6M | 97.0× | 3.8× | −0% | 4.2% | n/m |
| FLGTFulgent Genetics | $530.8M | n/m | 1.6× | +7% | −26.0% | n/m |
| MASS908 Devices | $422M | n/m | 6.9× | +13% | −57.0% | n/m |
| TKNOAlpha Teknova | $376.4M | n/m | 8.6× | +12% | −38.4% | n/m |
| NAUTNautilus Biotechnologycaveat | $297.4M | n/m | n/m | n/m | n/m | n/m |
| BDSXBiodesix | $229.8M | n/m | 2.2× | +34% | −27.0% | n/m |
| XGNExagen | $203.3M | n/m | 2.9× | +21% | −26.6% | n/m |
| MXCTMaxcyte | $149.6M | n/m | 4.8× | −13% | n/m | n/m |
| QTRXQuanterix | $132.9M | n/m | 0.9× | +22% | −80.2% | n/m |
| FRNMFreenomecaveat | $119.7M | n/m | n/m | n/m | n/m | n/m |
| ICCCImmucell | $95.9M | 132× | 3.1× | +8% | 2.6% | n/m |
| SEERSeer | $95.8M | n/m | 6.7× | −13% | n/m | n/m |
| IMDXInsight Molecular Diagnostics | $93.6M | n/m | 56.0× | −61% | n/m | n/m |
| SERASera Prognostics | $78.5M | n/m | n/m | −35% | n/m | n/m |
| IBACIB Acquisition | $54.1M | n/m | n/m | n/m | n/m | n/m |
| HBIOHarvard Bioscience | $39.1M | n/m | 0.4× | −1% | −11.9% | n/m |
| RPIDRapid Micro Biosystems | $35.3M | n/m | 1.0× | +16% | n/m | n/m |
| EYPTEyePoint | $32.3M | n/m | 11.6× | −95% | n/m | n/m |
| PRPOPrecipio | $31.8M | n/m | 1.2× | +28% | −4.5% | n/m |
| ONMDOneMedNet | $25.4M | n/m | 17.4× | +217% | n/m | n/m |
| BNGOBionano Genomics | $13.7M | n/m | 0.5× | +10% | n/m | n/m |
| ASTCASTROTECH | $9.5M | n/m | 10.4× | −13% | n/m | n/m |
| AMSAmerican Shared Hospital Services | $8.3M | n/m | 0.3× | +4% | −5.8% | n/m |
| BMRABiomerica | $8M | n/m | 1.8× | −11% | n/m | n/m |
| ACONAclarioncaveat | $5.2M | n/m | 61.9× | +33% | n/m | n/m |
| CDIOCardio Diagnostics | $4.9M | n/m | n/m | −26% | n/m | n/m |
| QCLSQ/C Technologies | $3.4M | n/m | n/m | n/m | n/m | n/m |
| ADVBAdvanced Biomedcaveat | $3.4M | n/m | n/m | n/m | n/m | n/m |
| BGLCBioNexus Gene Lab | $2.9M | n/m | 0.9× | −67% | −82.4% | n/m |
| VNRXVolitionrx | $2.9M | n/m | 1.2× | +86% | n/m | n/m |
| ISPCiSpecimencaveat | $2.1M | n/m | 4.5× | −92% | n/m | n/m |
| BIAFbioAffinity Technologies | $1.6M | n/m | 0.3× | −23% | n/m | n/m |
Rankings of diagnostics and research stocks
- Diagnostics and research stocks with the lowest PE ratio
- Diagnostics and research stocks cheapest against their own PE history
- Diagnostics and research stocks with the lowest price to sales ratio
- Diagnostics and research stocks with the lowest EV/EBIT
- Diagnostics and research stocks with the highest free cash flow yield
- Diagnostics and research stocks with the fastest revenue growth
- Diagnostics and research stocks with the fastest expected revenue growth
- Diagnostics and research stocks with the fastest earnings growth
- Diagnostics and research stocks with the highest profit margins
Other industries in Healthcare
Valuation data, not investment advice. Each company's page has its story, charts, financials and peers.